This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Antiviral Activity of AZD7295 in HCV Carriers

This study has been completed.
Information provided by:
Arrow Therapeutics Identifier:
First received: October 28, 2008
Last updated: March 30, 2010
Last verified: March 2010
PK, safety study of AZD7295 in HCV carriers

Condition Intervention Phase
Hepatitis C Drug: AZD7295 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, DB, PC Study to Determine the PK, Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of AZD7295 in Otherwise Healthy Male and Female Hepatitis C Carriers With Compensated Liver Disease

Resource links provided by NLM:

Further study details as provided by Arrow Therapeutics:

Primary Outcome Measures:
  • Plasma AZD7295 concentrations and pharmacokinetics [ Time Frame: 5 days ]

Enrollment: 31
Study Start Date: November 2008
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1 Drug: Placebo
matched placebo
Active Comparator: 2 Drug: AZD7295
700mg per day maximum


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HCV carrier

Exclusion Criteria:

  • concurrent medications
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00781976

New Zealand
Prof Ed Gane
Auckland, New Zealand
Sponsors and Collaborators
Arrow Therapeutics
Principal Investigator: Ed Gane Auckland Clinical Services
  More Information

Responsible Party: Liz Clark, Arrow Therapeutics Identifier: NCT00781976     History of Changes
Other Study ID Numbers: HCV689-102
Study First Received: October 28, 2008
Last Updated: March 30, 2010

Additional relevant MeSH terms:
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Antiviral Agents
Anti-Infective Agents processed this record on August 16, 2017